COSEHC warren trust cardiovascular fellowship

5-YEAR REPORT2003-2007

SELECTION CRITERIAOBJECTIVE: To support career training and primary research individuals in cardiovascular disease in the Southeastern United

States

SCIENCE FOCUS: Research broadly related to cardiovascular disease and function, stroke, or to related clinical, basic science, bioengineering and/or public health problem

DISCIPLINES: All basic and clinical disciplines in medicine

SITE of WORK: Fellowship and work must be at medical institution in the Southeastern United States as defined by COSEHC

SCOPE OF WORK: All projects must be done in accordance with NIH guidelines for research involving animals or human researchREQUIREMENTS: Completed either a MD, PhD, DrPH, or DO at time of award

CITIZENSHIP: Must be a citizen or non-citizen national of the United States or must have been lawfully admitted for permanent residence (i.e., in possession of a currently valid Alien Registration Receipt Card I-551, or some other legal verification of such status).Non-citizen nationals are generally persons born in outlying possessions of the United States (e.g., American Samoa and Swains Island). Individuals on temporary or student visas are not eligible.

ANNUAL AWARD: $ 3O,OOO including fringe benefits; $ 5000 may be used for project support. 65% of the funding will be given at the time of the award, with the remainder given at the completion of the fellowship, after receipt of a satisfactory final report. At least forty hours per week during the Fellowship must be dedicated tothe research program. Within the 40 hours per week training period, research trainees who are also training as clinicians must devote their time to the proposed research work and must confine clinical duties to only thosethat are an integral part of the research training experience.

SELECTION CRITERIA

AWARD DURATION: ONE year. Applicant may apply for one additional year of funding at the midpoint of initial grant (by 12/30)

PEER REVIEW: Prospective applicant must author application; evaluation will include applicant’s qualifications and research ability and previous accomplishments. Preference will be given to applicants trained within the southeastern US.

RESTRICTIONS: Applicant can have no more than 3-years post-doctoral experience at time of the award. Must not have a faculty appointment. Institution or other funding agency may supplement fellowship award

REPORTING: Progress report due at mid-term (6 months after award), and a Final report at the end of the fellowship.

Publications, monographs, and manuscripts resulting from the award must acknowledge COSEHC support.

SELECTION: Applications will be reviewed by the COSEHC Fellowship Committee, which will recommend a candidate to the Board for final approval

*COSEHC reserves the right not to award the fellowship if, in the opinion of the fellowship review committee, there is not a suitable applicant.

2003

XIAOYAN ZHOU, MD, PhD

CHINA

COSEHC CARDIOVASCULAR POSTDOCTORAL FELLOW 2003 TITLE: “EFFECTS OF SPECIFIC ALDOSTERONE RECEPTOR

ANTAGONISM ON GLOMERULAR DYNAMICS AND HISTOPATHOLOGY IN L-NAME/SHR MODEL”

LAB: OCHSNER CLINIC FOUNDATION NEW ORLEANS, LOUISIANA/Edward D. Frohlich, MD

Dr. Zhou is currently Senior Research Biologist Merck Research Laboratories Rahway, New Jersey

CITATIONS

1. Zhou X, Ono H, Ono Y, Frohlich ED. Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol. 2003 July-Aug;23:214-221.

2. Zhou X, Frohlich ED. Ageing, hypertension and the kidney: new data on an old problem. Nephrol Dial Transplant. 2003 Aug;18:1442-1445.

3. Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004 Mar-Apr;24: 242-249. ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP.

4. Zhou X, Matavelli L, Ono H, Frohlich ED. Superiority of combination of thiazide with ACE inhibitor or AT1 receptor blocker over thiazide alone on renoprotection. American Journal of Physiology 2005; 289:F871-879.

5. Zhou X, Frohlich ED. Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric oxide suppressed rats. Am J Nephrol 2005 Mar-Apr;25:138-152.

6. Zhou X, Frohlich ED. Physiological evidence of antihypertensive renoprotection. Current Opin Cardiol. 2005 July;20:290-295. 7. Zhou X, Matavelli L, Frohlich ED. Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr

Hypertens Rep. 2006 May;8:20-124. 8. Zhou X, Frohlich ED. Cardiac and renal complications in essential hypertension: analogy with aged spontaneously hypertensive rats

(SHR) or a young adult model using nitric oxide synthesis inhibition. Med Chem. 2007 Jan;3(1):61-65. 9. Zhou X, Frohlich ED. Arteriolar nephrosclerosis. Encyclopedic Reference of Molecular Mechanisms of Disease, edited by Professor

Dr. Florian Lang, Springer, 2007, in press. 10. Matavelli LC, Zhou X, Frohlich ED. Hypertensive renal vascular disease and cardiovascular endpoints. Curr Opin Cardiol. 2006

July;21:305-309. 11. Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED. Salt-loading produces severe renal hemodynamic dysfunction independent of

arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H814-9. Epub 2006 Sep 22

2004

MING-SHENG ZHOU, MD, PhD

CHINA

COSEHC CARDIOVASCULAR POSTDOCTORAL FELLOW 2004 TITLE: “STATINS AND HYPERTENSIVE CARDIOVACULAR AND

RENAL INJURY IN SALT-SENSITIVE HYPERTENSION” LAB: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE HYPERTENSION/NEPHROLOGY SECTION

VASCULAR BIOLOGY INSTITUTE/Leopoldo Raij, MD

Dr. Zhou is currently Assistant Professor, University of Miami School of Medicine, Vascular Biology Institute.

CITATIONS1: Shi JX, Zhou MS, Kong FT, Liu J. [Clinical observation on intravenous injection of aminophyline in 52 cases withcardiac sudden arrest unresponding to epinephrine.]Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 Nov;16(11):690-1. Chinese. Noabstract available.PMID: 15535916 [PubMed - in process]2: Xiang QY, Liang YX, Chen BH, Wang CS, Zhen SQ, Chen LS, Zhou MS, Li JF. [Study on the application of benchmark dose and biological monitoring indexes of fluorides in drinking water]Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Jul;38(4):261-4. Chinese.PMID: 15312588 [PubMed - indexed for MEDLINE]3: Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension.Semin Nephrol. 2004 Jul;24(4):366-78. Review.PMID: 15252776 [PubMed - indexed for MEDLINE]4: Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role ofeNOS and oxidant stress.Hypertension. 2004 Aug;44(2):186-90. Epub 2004 Jul 6.PMID: 15238570 [PubMed - indexed for MEDLINE]ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP.

CITATIONS5: Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function byamlodipine in angiotensin II-infused rats.Am J Hypertens. 2004 Feb;17(2):167-71.PMID: 14751660 [PubMed - indexed for MEDLINE]6: Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II,atherogenesis, and blood pressure.Hypertension. 2006 Jan;47(1):81-6. Epub 2005 Dec 12.PMID: 16344366 [PubMed - indexed for MEDLINE]7: Zhou MS, Jaimes EA, Raij L.Vascular but not cardiac remodeling is associated with superoxide production inangiotensin II hypertension.J Hypertens. 2005 Sep;23(9):1737-43.PMID: 16093920 [PubMed - indexed for MEDLINE]8: Schulman IH, Zhou MS, Raij L.Nitric oxide, angiotensin II, and reactive oxygen species in hypertension andatherogenesis.Curr Hypertens Rep. 2005 Feb;7(1):61-7. Review.PMID: 15683588 [PubMed - indexed for MEDLINE]

CITATIONS9: Hernandez Schulman I, Zhou MS, Raij L.Cross-talk between angiotensin II receptor types 1 and 2: potential role invascular remodeling in humans.Hypertension. 2007 Feb;49(2):270-1. Epub 2006 Dec 11. Review. No abstractavailable.PMID: 17159080 [PubMed - indexed for MEDLINE]10: Zhou MS, Jaimes EA, Raij L. Benazepril combined with either amlodipine or hydrochlorothiazide is moreeffective than monotherapy for blood pressure control and prevention of end-organinjury in hypertensive Dahl rats.J Cardiovasc Pharmacol. 2006 Jul;48(1):857-61.PMID: 16891915 [PubMed - indexed for MEDLINE]11: Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role inatherosclerosis and hypertension.J Hypertens Suppl. 2006 Mar;24(1):S45-50. Review.PMID: 16601573 [PubMed - indexed for MEDLINE]12: Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II,atherogenesis, and blood pressure.Hypertension. 2006 Jan;47(1):81-6. Epub 2005 Dec 12.PMID: 16344366 [PubMed - indexed for MEDLINE]

CITATIONS13: Sierra-Alvarez R, Hollingsworth J, Zhou MS.Removal of copper in an integrated sulfate reducing bioreactor-crystallizationreactor system.Environ Sci Technol. 2007 Feb 15;41(4):1426-31.PMID: 17593752 [PubMed - indexed for MEDLINE]14: Schulman IH, Zhou MS, Jaimes EA, Raij L. Dissociation between metabolic and vascular insulin resistance in aging.Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H853-9. Epub 2007 Apr 13.PMID: 17434977 [PubMed - indexed for MEDLINE]15: Zhou MS. Upregulation of nitric oxide, inhibition of oxidative stress, andantihypertensive effects of statins.Hypertension. 2007 Jun;49(6):e43; author reply e44. Epub 2007 Apr 2. No abstract available.PMID: 17404175 [PubMed - indexed for MEDLINE]16: Hernandez Schulman I, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role invascular remodeling in humans.Hypertension. 2007 Feb;49(2):270-1. Epub 2006 Dec 11. Review. No abstractavailable.PMID: 17159080 [PubMed - indexed for MEDLINE]

2005 (6 months)

FADY T. BOTROS, PhD

EGYPT

COSEHC CARDIOVASCULAR POSTDOCTORAL FELLOW 2005 (6 MONTHS) TITLE: “THE ROLE OF HEME OXYGENASE IN REGULATING THE

RENAL AFFERENT ARTERIOLE” LAB: TULANE UNIVERSITY PHYSIOLOGY DEPARTMENT/L. Gabriel Navar, PhD Dr. Botros is currently Research Instructor, Department of Physiology, Tulane University Health Sciences Center

CITATIONS1: Botros FT, Schwartzman ML, Stier CT Jr, Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension.Kidney Int. 2005 Dec;68(6):2745-55.PMID: 16316349 [PubMed - indexed for MEDLINE]2: Olszanecki R, Rezzani R, Omura S, Stec DE, Rodella L, Botros FT, Goodman AI,Drummond G, Abraham NG. Genetic suppression of HO-1 exacerbates renal damage: reversed by an increase in the antiapoptotic signaling pathway.PMID: 16940561 [PubMed - indexed for MEDLINE]3: Botros FT, Navar LG.Interaction between endogenously produced carbon monoxide and nitric oxide inregulation of renal afferent arterioles.Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2772-8. Epub 2006 Jul 14.PMID: 16844915 [PubMed - indexed for MEDLINE]4: Botros FT, Olszanecki R, Prieto-Carrasquero MC, Goodman AI, Navar LG, Abraham NG. Induction of heme oxygenase-1 in renovascular hypertension is associated withinhibition of apoptosis.Cell Mol Biol (Noisy-le-grand). 2007 May 15;53(4):51-60.PMID: 17531161 [PubMed - indexed for MEDLINE]ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP5: Mitchell KD, Botros FT, Navar LG. Intrarenal renin-angiotensin system and counteracting protective mechanisms inangiotensin II-dependent hypertension.Acta Physiol Hung. 2007 Mar;94(1-2):31-48. Review.PMID: 17444274 [PubMed - indexed for MEDLINE]ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP

2006

MARIA ANTONIA GARCIA-ESPINOSA, PhD

COSEHC CARDIOVASCULAR POSTDOCTORAL FELLOW 2006 TITLE: “RENIN INHIBITION VERSUS CONVERTING ENZYME

INHIBITION OR AT1 RECEPTOR BLOCKADE IN BRAIN: ASSESSMENT OF BLOOD PRESSURE LOWERING AND END-ORGAN PROTECTION”

LAB: WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE/ Debra Diz, PhD Dr. Garcia-Espinosa is currently a Research Fellow at Wake Forest University Health Sciences.

2007

ROMER ANDRES GONZALEZ VILLALOBOS, MD, PhD VENEZUELA

COSEHC CARDIOVASCULAR POSTDOCTORAL FELLOW 2007 TITLE: “ANGIOTENSIN II INTERNALIZATION – VIA THE AT1R – IS

REQUIRED FOR ANGIOTENSINOGEN GENE ACTIVATION IN PROXIMAL TUBULE CELLS”

LAB: TULANE UNIVERSITY HEALTH SCIENCES CENTER DEPARTMENT OF PHYSIOLOGY/L. Gabriel Navar, PhD Dr. Gonzalez-Villalobos is currently a Postdoctoral Research Fellow, Tulane University, Department of Physiology and the Renal and Hypertension Center of Excellence.